Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Immunotherapy for advanced melanoma Fang L; Lonsdorf AS; Hwang STJ Invest Dermatol 2008[Nov]; 128 (11): 2596-2605Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed. The first two strategies have yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen has resulted in objective response rates approaching 50%. For a number of reasons, lymphodepletion appears to be critical for maintenance of circulating antitumor T cells following adoptive cell transfer. Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain challenging and potentially life-threatening issues.|Adoptive Transfer/methods[MESH]|Animals[MESH]|CD8-Positive T-Lymphocytes/drug effects/pathology[MESH]|Cancer Vaccines/pharmacology/therapeutic use[MESH]|Disease Models, Animal[MESH]|Humans[MESH]|Immunotherapy/*methods[MESH]|Melanoma/immunology/pathology/*therapy[MESH]|Mice[MESH]|Skin Neoplasms/immunology/pathology/*therapy[MESH] |